TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06269796

Intervention type: DIAGNOSTIC_TEST
Intervention: Little Developmental Coordination Disorder Questionnaire (LDCDQ)
Description: The Little Developmental Coordination Disorder Questionnaire (LDCDQ) is a parent questionnaire consisting of 15 items designed to screen for motor coordination difficulties in 3- and 4-year-old children. It comprises 15 items grouped into two distinct factors: gross motor skills and fine motor skills. A Likert scale is used, ranging from one to five, where one (1) indicates Not at all like your child and five (5) indicates Very much like your child. The total of the 15 items is added up to obtain a total score of 75.
Study: NCT05080166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview with Clinicians
Description: One time, qualitative interview of clinicians for feedback on UPLYFT intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Field Test of UPLYFT with Lymphoma Survivors
Description: 6 session of UPLYFT intervention with Lymphoma Survivors for feedback

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pilot of UPLYFT with Lymphoma Survivors
Description: 6 session of UPLYFT intervention with Lymphoma Survivors
Study: NCT06269796

Intervention type: DIAGNOSTIC_TEST
Intervention: Bruininks- Oseretsky Test of Motor Proficiency 2nd Edition (BOT-2)
Description: The BOT-2 is standardized for children and adolescents aged 4 to 21 years and 11 months, and the full test takes 45 to 60 minutes to perform. The BOT-2 test was used to detect deviation from the norm and the likelihood of a diagnosis for DCD. The BOT-2 measures fine and gross motor proficiency, with subtests focusing on stability, mobility, strength, coordination, and object manipulation.
Study: NCT04946097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gross Myofascial Release
Description: Gross Myofascial Release : is amanual technique in form of Stretch of the Posterior Cervical Musculature and Gross stretch of gross Myofascial Release upper quarter: Arm Pull for duration of 10-15 min per session each stretch position was healed for 90sec

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional selected exercise program
Description: stretching exercises for cervical muscles and pectoralis major and source of heat in form of hot packs for 15 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional selected exercise program
Description: stretching exercises for cervical muscles and pectoralis major and source of heat in form of hot packs for 15 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Transcutaneous electrical nerve stimulation (TENS) is a method of pain relief involving the use of electrical current, the electrode placement on the course of pain for 15 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Transcutaneous electrical nerve stimulation (TENS) is a method of pain relief involving the use of electrical current, the electrode placement on the course of pain for 15 minutes
Study: NCT05180760

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone app use
Description: Smartphone app use in the active arm

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of care
Description: Standard of care
Study: NCT04892355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Root canal irrigation
Description: Devices used during root canal irrigation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Root canal irrigation
Description: Devices used during root canal irrigation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Root canal irrigation
Description: Devices used during root canal irrigation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Root canal irrigation
Description: Devices used during root canal irrigation
Study: NCT05859724

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NM26-2198
Description: IL-4R/IL-31 bispecific antibody for subcutaneous administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for NM26-2198
Study: NCT04880564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN1, 0.5mg/kg and CN401, 400mg
Description: CN1(0.5mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(400mg) will be administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN1, 1mg/kg and CN401, 600mg
Description: CN1(1mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(600mg) will be administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN1, 1mg/kg and CN401, 800mg
Description: CN1(1mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(800mg) will be administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN1, 3mg/kg and CN401, 800mg
Description: CN1(3mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(800mg) will be administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN1, 10mg/kg and CN401, 800mg
Description: CN1(10mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(800mg) will be administered orally twice daily.
Study: NCT02739581

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Variceal Ligation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Variceal Ligation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non selective beta blocker

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT04662554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-mm Resolution Clinical PET camera
Description: 1-Millimeter Resolution Clinical PET System in Head and Neck Cancer (HNC) Imaging
Study: NCT05371301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Carboplatin
Description: Paclitaxel 175mg/m2 iv d1 followed by Carboplatin(AUC=5) iv d1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: debulking surgery
Description: Remove all visible tumors and any other tissues or organs where tumor may have spread, which may include:~Uterus Fallopian tubes Omentum (tissue that covers the stomach, large intestine and other abdominal organs) Lymph nodes Diaphragm Part of the large bowel Spleen Parts of the liver

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: debulking surgery
Description: Remove all visible tumors and any other tissues or organs where tumor may have spread, which may include:~Uterus Fallopian tubes Omentum (tissue that covers the stomach, large intestine and other abdominal organs) Lymph nodes Diaphragm Part of the large bowel Spleen Parts of the liver
Study: NCT06529185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The BREATHER
Description: The BREATHER is Light/Medium resistance inspiratory muscle trainer which has significance role in increasing inspiratory muscle strength and endurance which could result in a decreased sensation of dyspnea

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological treatment
Description: patient will receive the usually pharmacological treatment.
Study: NCT05238792

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor-associated antigen-specific T cell (TAA-T)
Description: Patients will receive an infusion of partially HLA-matched TAA-T any time \>1 week after completing most recent course of conventional (non-investigational) therapy for their disease. For the lymphodepletion cohort, patients will receive lymphodepletion (LD) chemotherapy \>2 weeks from most recent course of conventional therapy and will nadir and recover before beginning TAA-T therapy. Patients will be enrolled to one of the following TAA-T dose levels:~BSA \<1.20 BSA ≥1.20 Dose level 1 without LD (low dose) 2x107 cells 4x107 cells Dose level 2 (LD + Low dose) 2x107 cells 4x107 cells Dose level 3 (LD + High dose) 4x107 cells 8x107 cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor-associated antigen-specific T cell (TAA-T)
Description: Patients will receive an infusion of partially HLA-matched TAA-T any time \>1 week after completing most recent course of conventional (non-investigational) therapy for their disease. For the lymphodepletion cohort, patients will receive lymphodepletion (LD) chemotherapy \>2 weeks from most recent course of conventional therapy and will nadir and recover before beginning TAA-T therapy. Patients will be enrolled to one of the following TAA-T dose levels:~BSA \<1.20 BSA ≥1.20 Dose level 1 without LD (low dose) 2x107 cells 4x107 cells Dose level 2 (LD + Low dose) 2x107 cells 4x107 cells Dose level 3 (LD + High dose) 4x107 cells 8x107 cells
Study: NCT06296771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary energy restriction and exercise group (D+E)
Description: The individuals within the dietary energy restriction and exercise group will be instructed to reduce their habitual energy intake by 5,000 kcal per week while taking part in physical exercise with a frequency of three sessions per week of HIIT and two sessions per week of resistance exercise throughout a duration of 8 weeks. Sessions can be performed in any order, but we will recommend alternating HIIT and resistance training days and taking the two rest days separately to allow for recovery.~The exercise programme will start the session by participating in a gentle stretching routine with the objective of reducing the effects of exercise-induced shoulder discomfort. The treatment focuses on the four main muscle groups in the upper body: the latissimus dorsi, the triceps, the rhomboid, the pectoral, and the upper trapezius. Each pose is held in the stretched position for a length of 15 seconds throughout each set, for a total of 4 sets.
Study: NCT06105775

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nitrate-enriched Beetroot Extract Capsule
Description: Starting from the 16th week of gestation and continuing for 22 weeks (154 days) or until delivery, whichever comes first, participants will consume a daily capsule containing beetroot extract enriched with 400 mg of sodium nitrate. Participants will maintain standard pre-eclampsia prophylaxis (acetylsalicylic acid 100mg nightly until 36 weeks of gestation and calcium carbonate 1000mg daily until delivery) and regular antihypertensive treatment.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: From the 16th week of gestation and lasting 22 weeks (154 days) or until delivery, participants will consume a daily capsule containing beetroot extract with the nitrate replaced by plant-based flour, design to mimic the appearance of the active capsule. Participants will maintain standard pre-eclampsia prophylaxis (acetylsalicylic acid 100mg nightly until 36 weeks of gestation and calcium carbonate 1000mg daily until delivery) and regular antihypertensive treatment.
Study: NCT06580834

Intervention type: DEVICE
Intervention: Cergenx Wave
Description: Short EEG recording using EEG amplifier with cloud based algorithm to assess brain injury.

Intervention type: DEVICE
Intervention: Cergenx Wave
Description: Short EEG recording using EEG amplifier with cloud based algorithm to assess brain injury.
Study: NCT05894434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multisensory Training
Description: The procedure involves repeatedly presenting identical visual-auditory stimuli at a single location in the hemianopic field (initially at 45° of eccentricity along the azimuth) while the patient maintains central fixation (0°, 0°). The visual (a 500 ms flash) and auditory (500 ms broadband noise burst) stimuli are in spatial and temporal congruence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multisensory Training
Description: The procedure involves repeatedly presenting identical visual-auditory stimuli at a single location in the hemianopic field (initially at 45° of eccentricity along the azimuth) while the patient maintains central fixation (0°, 0°). The visual (a 500 ms flash) and auditory (500 ms broadband noise burst) stimuli are in spatial and temporal congruence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multisensory Training
Description: The procedure involves repeatedly presenting identical visual-auditory stimuli at a single location in the hemianopic field (initially at 45° of eccentricity along the azimuth) while the patient maintains central fixation (0°, 0°). The visual (a 500 ms flash) and auditory (500 ms broadband noise burst) stimuli are in spatial and temporal congruence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multisensory Training
Description: The procedure involves repeatedly presenting identical visual-auditory stimuli at a single location in the hemianopic field (initially at 45° of eccentricity along the azimuth) while the patient maintains central fixation (0°, 0°). The visual (a 500 ms flash) and auditory (500 ms broadband noise burst) stimuli are in spatial and temporal congruence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unisensory Training
Description: The procedure involves repeatedly presenting identical auditory stimuli (500 ms broadband noise burst) at a single location in the hemianopic field (initially at 45° of eccentricity along the azimuth) while the patient maintains central fixation (0°, 0°).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unisensory Training
Description: The procedure involves repeatedly presenting identical auditory stimuli (500 ms broadband noise burst) at a single location in the hemianopic field (initially at 45° of eccentricity along the azimuth) while the patient maintains central fixation (0°, 0°).
Study: NCT05077787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage therapy
Description: Massage therapy includes stroking, kneading, rolling, tapping, vibration and effleurage over the face, chest ,abdomen and back. Massage therapy will be given for 5 minutes and will be repeated twice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinaesthetic stimulation
Description: Kinaesthetic stimulation includes passive flexion and extension movements of shoulder joint, elbow joint, hip joint, knee joint and both lower limbs together. It will be given for 5 minutes in each intervention
Study: NCT05539573

Intervention type: DEVICE
Intervention: Planned TAVI with the ACURATE neo2™ aortic bioprosthesis and ACURATE neo2™ transfemoral delivery system.
Description: The study will collect data from patients treated with the ACURATE neo2™ and its transfemoral delivery system following standard TAVI practice at each participating center. All patients will be followed to 12 months after the implant procedure. The study is divided into three periods:~1. Screening period: from screening to enrollment if study criteria are met.~2. Implantation procedure: immediately pre-implant to 24 hours post-procedure.~3. Follow-up period: at hospital discharge, at 30 days and at 12 months post-procedure.
Study: NCT04962126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab 25 MG/1 ML Intravenous Solution
Description: For intravenous infusion during:~Induction phase: Day 1, 8 and 15 of cycle 1 \& Day 1 of cycle 2-6 (q3/52); Maintenance phase: Day 1 of each cycle (q8/52) for up to 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 MG/40mL Intravenous Solution
Description: For intravenous infusion during induction phase only day 1 of each cycle q3/52 for up to 6 cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 4 Gy in 2 fractions
Description: Involved site radiotherapy will only be administered to participants to achieve a PR/SD after at restaging after cycle 2, treatment will be between cycle 3 and 4 of induction treatment.
Study: NCT06095726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peppermint Inhalation
Description: The researcher applied two drops (0,2ml) of 2% essential oil of peppermint on a piece of cotton. Then, each child was instructed to take three breaths of the essence that had been put on a piece of cotton before starting chemotherapy session with three minutes. In addition, the piece of cotton with peppermint essence was kept at bed side table to use by child as needed throughout the chemotherapy session. Inhalation of peppermint essence was applied for three consecutive chemotherapy sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Swedish Massage
Description: Children were received Swedish massage therapy for twenty minutes prior to chemotherapy session in a private and special room with effleurage, petrissage, friction, and tapotement and vibration movements for three consecutive chemotherapy sessions. The researcher applied facilitating olive oil in hands and pre warmed before applying massage. The massage technique was applied in prone position with mild to moderate pressure with guidance by the child's feedback and tolerance by using non-scented olive oil. Children's privacy was considered.
Study: NCT04769427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDO max threads
Description: To determine the effects of absorbable Polydioxanone (PDO) thread non-surgical rhinoplasty on quality of life (FACE-Q scale)
Study: NCT06372925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: 20mg atorvastatin PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: 20mg atorvastatin PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVUS/OCT
Description: performed the IVUS/OCT at baseline and Day 360

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVUS/OCT
Description: performed the IVUS/OCT at baseline and Day 360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inclisiran
Description: Inclisiran 284mg SC
Study: NCT06513299

Intervention type: DEVICE
Intervention: low tidal volume
Description: Patients ventilated with assist/control modes of mechanical ventilation with tidal volume between 6.0 ml/kg PBW and 8.0 ml/kg PBW with PPLAT ≤ 30 cmH2O, until weaning criteria are met: P/F ratio \> 250 mmHg; PEEP ≤ 8 cmH2O and lower than the previous day; FiO2 \< 0.5 and lower than the previous day; systolic arterial pressure ≥ 85 mmHg.

Intervention type: DEVICE
Intervention: high tidal volume
Description: Patients ventilated with assist/control modes of mechanical ventilation with tidal volume between 8.0 ml/Kg PBW and 10.0 ml/kg PBW with PPLAT ≤ 30 cmH2O, until weaning criteria are met: P/F ratio \> 250 mmHg; PEEP ≤ 8 cmH2O and lower than the previous day; FiO2 \< 0.5 and lower than the previous day; systolic arterial pressure ≥ 85 mmHg.

Intervention type: DEVICE
Intervention: low driving pressure
Description: Patients ventilated with assist/control modes of mechanical ventilation with driving pressure between 7.0 cmH2O and 12.0 cmH2O with VT ≤ 10 ml/kg PBW, until weaning criteria are met: P/F ratio \> 250 mmHg; PEEP ≤ 8 cmH2O and lower than the previous day; FiO2 \< 0.5 and lower than the previous day; systolic arterial pressure ≥ 85 mmHg.

Intervention type: DEVICE
Intervention: high driving pressure
Description: Patients ventilated with assist/control modes of mechanical ventilation with driving pressure between 12.0 cmH2O and 18.0 cmH2O with VT ≤ 10 ml/kg PBW, until weaning criteria are met: P/F ratio \> 250 mmHg; PEEP ≤ 8 cmH2O and lower than the previous day; FiO2 \< 0.5 and lower than the previous day; systolic arterial pressure ≥ 85 mmHg.
Study: NCT06062901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in one-on-one interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT02301312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POSS-PCU vascular graft
Description: New vascular access graft
Study: NCT04578834

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to LNP023 200mg b.i.d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP023
Description: LNP023 200mg b.i.d
Study: NCT05520047

Intervention type: BEHAVIORAL
Intervention: COVID19-severe Patient
Description: Behavioral and social test assessment

Intervention type: BEHAVIORAL
Intervention: family of COVID19-severe Patient
Description: Behavioral and social test assessment
Study: NCT06580678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH001
Description: topical application of KH001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical application of Water for Injection
Study: NCT05146219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TY-9591 Tablets
Description: TY-9591 Tablets 160mg/d
Study: NCT04903288

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Eladocagene Exuparvovec
Description: Four 0.08 milliliters (mL) infusions at a dose of 0.45×10\^11 vg and a volume of 80 microliters (μl) per site to 4 sites (2 per putamen), for the total dose of 1.8×10\^11 vg and a total volume of 320 μl per participant.
Study: NCT04867369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 20mL 0.5%
Description: Interscalene nerve block with 20 mL 0.5% bupivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 20mL 0.5%
Description: Interscalene nerve block with 20 mL 0.5% bupivacaine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 20mL 0.25%
Description: Pecs II fascial plane block with 20 mL 0.25% bupivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine up to 15mL 0.25%
Description: Local infiltration of 0.25% bupivacaine by the surgeon, up to 15 mL.
Study: NCT06636981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort2: ATRA+Toripalimab+TPC
Description: Receive 200 mg D1 of Toripalimab via intravenous infusion for a course of 21 days; TPC regimen (monoclonal antibody 10mg/kg D1, 8 intravenous infusions, 1 course of treatment every 21 days; Elibulin 1.4mg/m2 D1, 8 intravenous infusions, 1 course of treatment every 21 days; Utideron 40mg/m2 D1-5 intravenous infusions, 1 course of treatment every 21 days; Gemcitabine 1000mg/m2 D1, 8 intravenous infusions, 1 course of treatment every 21 days; Albumin paclitaxel 100 mg/m2 D1, D8, intravenous infusion, 1 course of treatment every 21 days); Capecitabine 1000mg/m2, D1-14, oral, one course of treatment every 21 days); All trans retinoic acid 20 mg bid, orally, D-3-D11, administered continuously for 14 days, stopped for 7 days, with one course of treatment lasting 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort1: ATRA+Toripalimab+chemo
Description: Receive 200 mg of Toripalimab via D1 intravenous infusion, with 21 days as one course of treatment; Albumin paclitaxel 100 mg/m2, D1, D8, intravenous infusion, one course of treatment for 21 days; All trans retinoic acid 20 mg bid, oral, D-3-D11, continuous administration for 14 days, cessation for 7 days, 21 days is one course of treatment.